Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction

William E. Boden, Seth Baum, Peter P. Toth, Sergio Fazio, Deepak L. Bhatt

    Research output: Contribution to journal › Review article › peer-review

    14 Scopus citations

    Fingerprint

    Dive into the research topics of 'Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction'. Together they form a unique fingerprint.

    Medicine & Life Sciences